Impact Study of Meningococcal Conjugate Vaccination
The impact of meningococcal conjugate vaccination on pharyngeal carriage of serogroup A
meningococci and on transmission of the infection.
PI: Brian Greenwood
Funders: Wellcome trust and BMGF.
The African Meningococcal Carriage Consortium (MenAfriCar) was established in 2009 to determine the pattern of meningococcal carriage across the African meningitis belt before and after the introduction of a new serogroup A meningococcal conjugate vaccine (PsA-TT)(MenAfriVacR). The consortium involves seven partners situated across the African meningitis belt and a number of northern partners. MenAfriCar investigators working in Chad have shown the dramatic impact of this vaccine in halting an ongoing epidemic of meningitis caused by this bacterium. The vaccine was also very effective at preventing serogroup A meningococcal carriage. Over 60,000 samples have been collected during the course of cross-sectional and household surveys. Molecular characterisation of meningococci isolated from these samples, being undertaken at the University of Oxford, has nearly been completed together with serological studies which are being undertaken by the PHE Vaccine Evaluation unit at Manchester. Analysis of the data obtained from these surveys will allow the pattern of spread of meningococci in households to be determined as well as serological correlates of protection against carriage.Back